Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
about
Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell VaccinationNovel technologies and emerging biomarkers for personalized cancer immunotherapyTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsChemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomasImmunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse modelRole of IL-2 in cancer immunotherapyThe oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade.Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer.Immunotherapy for lung cancer: for whom the bell tolls?IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.Immunogenomics: using genomics to personalize cancer immunotherapy.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.Biomarkers associated with checkpoint inhibitors.Ipilimumab in melanoma.The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer.The immune contexture in cancer prognosis and treatment.Use of LDH and autoimmune side effects to predict response to ipilimumab treatment.Regulatory T cells impede acute and long-term immunity to blood-stage malaria through CTLA-4.BTLA identifies dysfunctional PD-1-expressing CD4+ T cells in human hepatocellular carcinoma.Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.Real-time monitoring of tumor progression and drug responses in a preclinical mouse model of prostate cancerCombinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.Predictors of responses to immune checkpoint blockade in advanced melanomaBiomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.Comparative genomics reveals that loss of lunatic fringe (LFNG) promotes melanoma metastasis.Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review.Control of NK Cell Activation by Immune Checkpoint Molecules.Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy.Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.IL-2 and Beyond in Cancer Immunotherapy.Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma.Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice.Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.Immune consequences of anti-angiogenic therapyin renal cell carcinoma.
P2860
Q26765345-32C8D0D2-EFBD-4CF5-BAEB-6B67C14A4519Q26770780-71DE078E-7DC7-4074-B822-644526CD1687Q26996518-1367F734-C074-4B5E-88D0-90CC695FDA61Q30358552-48A21FFB-0137-47D1-A813-8DD01D7C931AQ34522172-48AA7C24-1B73-4D68-9FBC-D35E5947213AQ36201411-F7CC09AE-06FF-4BB7-847C-0ABC4FEE1176Q36711007-A0EC14E7-E736-4579-B2B7-F5BC84C1F9A7Q36821149-4F3DF994-23FE-4E8D-BE6F-B06C5B7FA3FCQ37079072-2589025D-58A4-4BC6-A218-35363E53D656Q37181696-D5CF2577-7557-41B2-9D85-6575C9C6BEF1Q37616503-539CA3A3-D114-4569-B3CB-E7A8386940AFQ38367414-47E8487C-29D5-4C0C-B10E-2FED4413D501Q38768952-81414C2E-5F17-49F5-A43E-8E681FBF9654Q38772744-163FB2BD-D9F5-431C-8330-E8EA7E6DE4F6Q38775177-BCA22690-84D0-4F3E-92BE-0113628EA690Q38819537-D51D2111-1A15-4373-939B-22ED16AEA441Q38893697-5E95C1C2-A9AE-4993-A020-737A5BF47A56Q39338052-61861029-482D-4747-9894-D280C0B79F73Q39456999-BA02104D-1EC6-41BF-B022-EA7CA85DA3DBQ39532055-ADC3EB26-B36F-4106-84EF-03B797ED4339Q40047869-B4EEBE3E-D81E-48F3-8A96-76FFB4B05054Q40357836-18246E38-8426-4798-BEC2-36FF146AC82BQ40964128-05C5FF23-97C1-4253-858A-E2CCDC93F70EQ41561800-A2C53269-785D-4F57-B574-7653B14D2974Q41591613-C93E5ECB-1BC5-465A-A3D9-9D475D2838B2Q41701241-4E4BF6D5-C9FE-4956-9C07-430BDC2F9CDCQ42369277-6E37FF3A-34E3-4669-9898-A68EF0EAC809Q46177852-1905C151-C7C2-4B85-89DC-751F92764498Q46250385-B467F49F-0083-4AE6-B3B3-0164359FED75Q47105622-E854D80B-2A60-4938-939C-00B3507AA6A1Q47128718-78172D7F-74A6-48D0-8A53-A53EF3844B12Q47292249-4500D608-6CD9-4AE7-A14A-4970EFF0CEDDQ48244625-058A393E-2E10-4F89-A336-C39EA294D3B7Q48296904-EB0816CC-E531-4559-9198-218B869A45E6Q50004232-705AD975-D47C-4FEE-91C2-5263CA8D03D3Q52726999-501082A9-8D96-4384-9D04-7DD9560F8D9BQ53068034-0A0FCE6B-3B49-499E-AA59-1F8AF60C0CF7Q53695267-23954919-3C52-4CB9-B14B-E58B84D7E30BQ54218762-FD6EA34C-F675-41A0-B7C7-0CCD82E49EB4Q54981236-BAFF7A86-3827-45CE-9213-7150628B6FAB
P2860
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Anticancer immunotherapy by CT ...... nostic impact of soluble CD25.
@ast
Anticancer immunotherapy by CT ...... nostic impact of soluble CD25.
@en
type
label
Anticancer immunotherapy by CT ...... nostic impact of soluble CD25.
@ast
Anticancer immunotherapy by CT ...... nostic impact of soluble CD25.
@en
prefLabel
Anticancer immunotherapy by CT ...... nostic impact of soluble CD25.
@ast
Anticancer immunotherapy by CT ...... nostic impact of soluble CD25.
@en
P2093
P2860
P50
P356
P1433
P1476
Anticancer immunotherapy by CT ...... nostic impact of soluble CD25.
@en
P2093
Alan J Korman
Andrzej Mackiewicz
Antoni Ribas
Christine Mateus
David Enot
Dirk Jaeger
Dirk Schadendorff
Inka Zörnig
Jacek Mackiewicz
Jedd D Wolchok
P2860
P2888
P304
P356
10.1038/CR.2015.3
P50
P577
2015-01-13T00:00:00Z
P5875
P6179
1008573304